WO2016137235A2 - 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 - Google Patents
마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 Download PDFInfo
- Publication number
- WO2016137235A2 WO2016137235A2 PCT/KR2016/001828 KR2016001828W WO2016137235A2 WO 2016137235 A2 WO2016137235 A2 WO 2016137235A2 KR 2016001828 W KR2016001828 W KR 2016001828W WO 2016137235 A2 WO2016137235 A2 WO 2016137235A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- mirna
- mir
- seq
- rna
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Abstract
Description
Claims (10)
- miR-3670, miR-4477a, miR-8078로 구성된 군에서 선택되는 하나 이상의 miRNA를 유효 성분으로 포함하는 암 치료용 약학 조성물.
- 제1항에 있어서,상기 miR-3670 는 서열 번호 35와 서열 번호 36 또는 서열 번호 67의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miR-4477a 는 서열 번호 43과 서열 번호 44 또는 서열 번호 68의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miR-8078 는 서열 번호 65와 서열 번호 66 또는 서열 번호 69의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miRNA는 암 세포의 자살 기전을 유도하여 암을 치료하는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 암은 폐암, 간암, 위암, 대장암, 췌장암, 담낭 및 담도암, 유방암, 백혈병, 식도암, 비호치킨 림프종, 갑상선암, 자궁경부암, 피부암의 원발성 암과 이로부터 기타 장기로 전이되어 유발되는 전이암 및 비정상적인 과다 세포 분열을 촉진하여 생성되는 종양성 세포 질환으로 구성되는 군으로부터 선택된 1종 이상의 암인 것을 특징으로 하는 약학 조성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 miRNA는 miRNA유도체인 것을 특징으로 하는 조성물.
- 제7항에 있어서, 상기 miRNA 유도체는 RNA 인산 뼈대 구조 (phosphate backbone structure)를 황 등의 다른 원소로 치환한 형태인 포스포로사이오에이트 (phosphorothiolate) 구조를 부분적으로 포함하는 형태; RNA 대신 DNA, PNA(petide nucleic acids) 및 LNA(locked nucleic acid) 분자로의 전체 또는 부분적으로 치환된 형태; 및 RNA 당의 2’수산화기를 메틸화, 메톡시화, 플르오르화 등의 기능성 구조로 치환한 형태로 구성된 군에서 선택되는 것을 특징으로 하는 조성물.
- 제7항에 있어서, 상기 miRNA 유도체는 pri-miRNA 또는 precursor miRNA의 miRNA 전구체 형태; 또는 플라스미드 형태의 miRNA 전구체로 구성되는 것을 특징으로 하는 조성물.
- 제9항에 있어서, 상기 miRNA 전구체는 RNA 인산 뼈대 구조 (phosphate backbone structure)를 황 등의 다른 원소로 치환한 형태인 포스포로사이오에이트 (phosphorothiolate) 구조를 부분적으로 포함하는 형태; RNA 대신 DNA, PNA(petide nucleic acids) 및 LNA(locked nucleic acid) 분자로의 전체 또는 부분적으로 치환된 형태; 및 RNA 당의 2’수산화기를 메틸화, 메톡시화, 플르오르화 등의 기능성 구조로 치환한 형태로 구성된 군에서 선택되는 것을 특징으로 하는 조성물.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017132895A RU2686313C2 (ru) | 2015-02-25 | 2016-02-25 | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента |
US15/553,097 US10351849B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
EP16755885.7A EP3263135B1 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
AU2016224201A AU2016224201B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microRNA as active ingredient |
BR112017018318-8A BR112017018318A2 (ko) | 2015-02-25 | 2016-02-25 | A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient |
JP2017545217A JP6538183B2 (ja) | 2015-02-25 | 2016-02-25 | マイクロrnaを有効成分として含む癌治療用医薬組成物 |
CN201680018165.9A CN107454843B (zh) | 2015-02-25 | 2016-02-25 | 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物 |
CA2977624A CA2977624C (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
US16/371,026 US10612026B2 (en) | 2015-02-25 | 2019-03-31 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150026557 | 2015-02-25 | ||
KR10-2015-0026557 | 2015-02-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/553,097 A-371-Of-International US10351849B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
US16/371,026 Division US10612026B2 (en) | 2015-02-25 | 2019-03-31 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2016137235A2 true WO2016137235A2 (ko) | 2016-09-01 |
WO2016137235A3 WO2016137235A3 (ko) | 2016-10-20 |
WO2016137235A9 WO2016137235A9 (ko) | 2016-11-24 |
Family
ID=56789628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/001828 WO2016137235A2 (ko) | 2015-02-25 | 2016-02-25 | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10351849B2 (ko) |
EP (1) | EP3263135B1 (ko) |
JP (1) | JP6538183B2 (ko) |
KR (2) | KR101862080B1 (ko) |
CN (2) | CN113633656A (ko) |
AU (1) | AU2016224201B2 (ko) |
BR (1) | BR112017018318A2 (ko) |
CA (2) | CA2977624C (ko) |
RU (1) | RU2686313C2 (ko) |
WO (1) | WO2016137235A2 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058474A (zh) * | 2016-11-03 | 2017-08-18 | 中国人民解放军第三军医大学 | 一种通过血浆microRNA‑3591‑3p诊断急性高山病的诊断试剂盒 |
EP3505630A4 (en) * | 2016-08-24 | 2020-04-01 | Bioneer Corporation | DOUBLE-STRANDED OLIGO-RNA STRUCTURE COMPRISING A MICROARN |
CN111349704A (zh) * | 2020-03-17 | 2020-06-30 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
CN111405901A (zh) * | 2017-11-09 | 2020-07-10 | 国立大学法人广岛大学 | 含有miRNA的癌症治疗用医药组合物 |
US11820984B2 (en) * | 2018-01-30 | 2023-11-21 | Bioneer Corporation | Double-helix oligonucleotide construct comprising double-stranded miRNA and use thereof |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2951016A1 (en) | 2014-06-12 | 2015-12-17 | Toray Industries, Inc. | Prostate cancer detection kit or device, and detection method |
KR20180075139A (ko) | 2016-12-26 | 2018-07-04 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
KR102110103B1 (ko) * | 2017-06-16 | 2020-05-13 | (주)프로스테믹스 | 암의 예방 또는 치료용 약학적 조성물 |
WO2019103581A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |
KR102145176B1 (ko) * | 2017-11-27 | 2020-08-18 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
WO2019103300A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | Mirna를 포함하는 상처 치료 또는 피부 개선용 조성물 |
WO2019103572A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | Mirna를 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
CN107881237B (zh) * | 2017-12-01 | 2020-11-20 | 唐山市人民医院 | 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用 |
US10987428B2 (en) * | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
WO2020032228A1 (ja) * | 2018-08-10 | 2020-02-13 | 東レ株式会社 | 前立腺がんの検出のためのキット、デバイス及び方法 |
KR102178919B1 (ko) * | 2018-11-26 | 2020-11-13 | 순천향대학교 산학협력단 | 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도 |
KR102133205B1 (ko) | 2018-12-05 | 2020-07-13 | 충북대학교 산학협력단 | PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
KR102418779B1 (ko) * | 2018-12-12 | 2022-07-08 | (주)프로스테믹스 | 신규한 miRNA 유사체 및 이의 용도 |
WO2020235671A1 (ja) * | 2019-05-23 | 2020-11-26 | 国立大学法人大阪大学 | 性ホルモン非感受性greb1陽性腫瘍の治療剤 |
CN110184338B (zh) * | 2019-05-31 | 2023-04-07 | 南方医科大学第三附属医院(广东省骨科研究院) | 脑脊液外泌体miRNA在MMD诊断和治疗中的应用 |
WO2020246380A1 (ja) * | 2019-06-05 | 2020-12-10 | 株式会社キャンサーステムテック | 癌治療剤 |
KR102085260B1 (ko) | 2019-06-19 | 2020-03-05 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
CN110607368B (zh) * | 2019-09-19 | 2021-07-13 | 西安交通大学 | miRNA3926-1基因作为胰腺癌诊断和疗效标志物的应用 |
CN111467504A (zh) * | 2020-03-13 | 2020-07-31 | 南方医科大学 | miR-4469在制备抗结直肠癌药物中的应用 |
CN111387143A (zh) * | 2020-04-02 | 2020-07-10 | 华北理工大学 | miRNA-203a-3p在开发抑制胰腺癌药物中的应用 |
CN111466339A (zh) * | 2020-04-02 | 2020-07-31 | 华北理工大学 | miRNA-203a-3p在促进胰腺癌细胞增殖和迁移中的应用 |
WO2021240533A1 (en) * | 2020-05-29 | 2021-12-02 | National Institute Of Immunology | Dna damage dependent microrna signature for cancers, methods and uses related thereto |
CN114058697B (zh) * | 2020-07-29 | 2023-08-18 | 四川大学华西医院 | 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途 |
CN114058698B (zh) * | 2020-07-29 | 2023-08-15 | 四川大学华西医院 | 检测外泌体miR-6879-5p的试剂在制备甲状腺癌转移检测试剂盒中的用途 |
US20220119812A1 (en) * | 2020-10-20 | 2022-04-21 | Duquesne University Of The Holy Spirit | Micro rna interactions as therapeutic targets for covid-19 and other viral infections |
CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
EP4299078A1 (en) * | 2021-02-25 | 2024-01-03 | Bioneer Corporation | Composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded mirna as active ingredient |
CN113041255B (zh) * | 2021-04-13 | 2022-10-11 | 上海中医药大学 | 一种新发现miRNA–mRNA调控轴介导肺腺癌NCI-H1299细胞焦亡的方法 |
CN113981074A (zh) * | 2021-12-10 | 2022-01-28 | 石河子大学 | 一种与2型糖尿病相关的microRNA及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US15071A (en) * | 1856-06-10 | John h | ||
CN101228274A (zh) * | 2005-04-12 | 2008-07-23 | 布鲁塞尔大学 | 靶向半乳凝素-1的基于RNAi的方法用于治疗癌症的用途 |
WO2008154333A2 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
KR101325186B1 (ko) * | 2008-01-23 | 2013-11-07 | (주)바이오니아 | 이중가닥 miRNA를 유효성분으로 포함하는 항암제 |
WO2009128805A1 (en) * | 2008-04-17 | 2009-10-22 | The Johns Hopkins University | On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
WO2011069100A2 (en) | 2009-12-04 | 2011-06-09 | Duke University | Microrna and use thereof in identification of b cell malignancies |
CN103476947A (zh) * | 2011-03-02 | 2013-12-25 | 格路福生物制药公司 | 寡聚体的增强的生物分布 |
CN103505743A (zh) * | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | 含功能性microRNA/siRNA的细胞微粒子及其应用 |
CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
CA2930795A1 (en) * | 2012-11-16 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers |
WO2014100252A1 (en) * | 2012-12-18 | 2014-06-26 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate rna processing |
CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
-
2016
- 2016-02-25 RU RU2017132895A patent/RU2686313C2/ru active
- 2016-02-25 CA CA2977624A patent/CA2977624C/en active Active
- 2016-02-25 BR BR112017018318-8A patent/BR112017018318A2/ko not_active IP Right Cessation
- 2016-02-25 EP EP16755885.7A patent/EP3263135B1/en active Active
- 2016-02-25 WO PCT/KR2016/001828 patent/WO2016137235A2/ko active Application Filing
- 2016-02-25 CN CN202110786758.2A patent/CN113633656A/zh active Pending
- 2016-02-25 JP JP2017545217A patent/JP6538183B2/ja not_active Expired - Fee Related
- 2016-02-25 KR KR1020160022462A patent/KR101862080B1/ko active IP Right Grant
- 2016-02-25 CN CN201680018165.9A patent/CN107454843B/zh not_active Expired - Fee Related
- 2016-02-25 CA CA3134991A patent/CA3134991A1/en active Pending
- 2016-02-25 AU AU2016224201A patent/AU2016224201B2/en not_active Ceased
- 2016-02-25 US US15/553,097 patent/US10351849B2/en not_active Expired - Fee Related
-
2018
- 2018-05-15 KR KR1020180055329A patent/KR101960067B1/ko active IP Right Grant
-
2019
- 2019-03-31 US US16/371,026 patent/US10612026B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3505630A4 (en) * | 2016-08-24 | 2020-04-01 | Bioneer Corporation | DOUBLE-STRANDED OLIGO-RNA STRUCTURE COMPRISING A MICROARN |
US11123361B2 (en) | 2016-08-24 | 2021-09-21 | Bioneer Corporation | Double-stranded oligo RNA structure comprising miRNA |
CN107058474A (zh) * | 2016-11-03 | 2017-08-18 | 中国人民解放军第三军医大学 | 一种通过血浆microRNA‑3591‑3p诊断急性高山病的诊断试剂盒 |
CN107058474B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒 |
CN111405901A (zh) * | 2017-11-09 | 2020-07-10 | 国立大学法人广岛大学 | 含有miRNA的癌症治疗用医药组合物 |
US11820984B2 (en) * | 2018-01-30 | 2023-11-21 | Bioneer Corporation | Double-helix oligonucleotide construct comprising double-stranded miRNA and use thereof |
CN111349704A (zh) * | 2020-03-17 | 2020-06-30 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP6538183B2 (ja) | 2019-07-03 |
BR112017018318A2 (ko) | 2018-07-10 |
RU2686313C2 (ru) | 2019-04-25 |
RU2017132895A3 (ko) | 2019-03-25 |
US20180030440A1 (en) | 2018-02-01 |
US20190218555A1 (en) | 2019-07-18 |
WO2016137235A3 (ko) | 2016-10-20 |
US10351849B2 (en) | 2019-07-16 |
CA2977624C (en) | 2021-11-30 |
US10612026B2 (en) | 2020-04-07 |
AU2016224201B2 (en) | 2018-07-05 |
WO2016137235A9 (ko) | 2016-11-24 |
CN107454843B (zh) | 2021-07-30 |
KR101960067B1 (ko) | 2019-03-20 |
KR20180054549A (ko) | 2018-05-24 |
JP2018507866A (ja) | 2018-03-22 |
CN113633656A (zh) | 2021-11-12 |
CA3134991A1 (en) | 2016-09-01 |
EP3263135A4 (en) | 2018-09-19 |
CN107454843A (zh) | 2017-12-08 |
RU2017132895A (ru) | 2019-03-25 |
EP3263135A2 (en) | 2018-01-03 |
CA2977624A1 (en) | 2016-09-01 |
EP3263135B1 (en) | 2020-01-15 |
KR20160103949A (ko) | 2016-09-02 |
KR101862080B1 (ko) | 2018-07-04 |
AU2016224201A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016137235A9 (ko) | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 | |
Wu et al. | Suppression of cell growth and invasion by miR-205 in breast cancer | |
Khuu et al. | The three paralogous microRNA clusters in development and disease, miR-17-92, miR-106a-363, and miR-106b-25 | |
Barsotti et al. | p53-Dependent induction of PVT1 and miR-1204 | |
Smorag et al. | MicroRNA signature in various cell types of mouse spermatogenesis: evidence for stage‐specifically expressed miRNA‐221,‐203 and‐34b‐5p mediated spermatogenesis regulation | |
Zhang et al. | MicroRNA-148a promotes myogenic differentiation by targeting the ROCK1 gene | |
Shi et al. | MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells | |
Chen et al. | MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma | |
Yao et al. | MicroRNA-224 is involved in the regulation of mouse cumulus expansion by targeting Ptx3 | |
Liu et al. | Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo (a) pyrene-trans-7, 8-dihydrodiol-9, 10-epoxide | |
Cui et al. | miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′ UTR of CD46 | |
Kesanakurti et al. | Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer | |
Alteri et al. | Cyclin D1 is a major target of miR-206 in cell differentiation and transformation | |
Trakooljul et al. | Identification of target genes and pathways associated with chicken microRNA miR‐143 | |
US20230348911A1 (en) | Antisense oligonucleotides for modulation of long noncoding rnas | |
Wang et al. | LncRNA FAL1 promotes carcinogenesis by regulation of miR-637/NUPR1 pathway in colorectal cancer | |
Sciamanna et al. | Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression | |
Attema et al. | Identification of an enhancer that increases miR-200b~ 200a~ 429 gene expression in breast cancer cells | |
Yang et al. | Downregulation of microRNA‑34b is responsible for the elevation of blood pressure in spontaneously hypertensive rats | |
Zhang et al. | Identification of miR-2400 gene as a novel regulator in skeletal muscle satellite cells proliferation by targeting MYOG gene | |
Kong et al. | MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein | |
Xie et al. | Inhibition of microRNA‑30a prevents puromycin aminonucleoside‑induced podocytic apoptosis by upregulating the glucocorticoid receptor α | |
WO2008068047A1 (en) | Micro rna targeting ets1 | |
EP2464730B1 (en) | miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA | |
Du et al. | Discovery and functional characterization of microRNAs and their potential roles for gonadal development in spotted knifejaw, Oplegnathus punctatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16755885 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2977624 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017545217 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017018318 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2016755885 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016224201 Country of ref document: AU Date of ref document: 20160225 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017132895 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017018318 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170825 |